MGMolly Griffin

Molly Griffin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Molly Griffin has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Who does the fairness in health AI community represent?

    by Isabelle Rose I. Alberto, Nicole Rose I. Alberto, Yuksel Altinel, Sarah Blacker, William Warr Binotti, Leo Anthony Celi, Tiffany Chua, Amelia Fiske, Molly Griffin, Gulce Karaca, et al.

    OBJECTIVE: Artificial intelligence (AI) and machine learning are central components of today’s medical environment. The fairness of AI, i.e. the ability of AI to be free from bias, has repeatedly come into question. This study investigates the diversity of the members of academia whose scholarship poses questions about the fairness of AI. METHODS: The articles that combine the topics of fairness, artificial intelligence, and medicine were selected from Pubmed, Google Scholar, and Embase using keywords. Eligibility and data extraction from the articles were done manually and cross-checked by another author for accuracy. 375 articles were selected for further analysis, cleaned, and organized in Microsoft Excel; spatial diagrams were generated using Public Tableau. Additional graphs were generated using Matplotlib and Seaborn. The linear and logistic regressions were analyzed using Python. RESULTS: We identified 375 eligible publications, including research and review articles concerning AI and fairness in healthcare. When looking at the demographics of all authors, out of 1984, 794 were female, and 1190 were male. Out of 375 first authors, 155 (41.33%) were female, and 220 (58.67%) were male. For last authors 110 (31.16%) were female, and 243 (68.84%) were male. In regards to ethnicity, 234 (62.40%) of the first authors were white, 103 (27.47%) were Asian, 24 (6.40%) were black, and 14 (3.73%) were Hispanic. For the last authors, 234 (66.29%) were white, 96 (27.20%) were Asian, 12 (3.40%) were black, and 11 (3.11%) were Hispanic. Most authors were from the USA, Canada, and the United Kingdom. The trend continued for the first and last authors of the articles. When looking at the general distribution, 1631 (82.2%) were based in high-income countries, 209 (10.5 %) were based in upper-middle-income countries, 135 (6.8%) were based in lower-middle-income countries, and 9 (0.5 %) were based in low-income countries. CONCLUSIONS: Analysis of the bibliographic data revealed that there is an overrepresentation of white authors and male authors, especially in the roles of first and last author. The more male authors a paper had the more likely they were to be cited. Additionally, analysis showed that papers whose authors are based in higher-income countries were more likely to be cited more often and published in higher impact journals. These findings highlight the lack of diversity among the authors in the AI fairness community whose work gains the largest readership, potentially compromising the very impartiality that the AI fairness community is working towards.


  • Using machine learning to parse breast pathology reports

    by Adam Yala, Regina Barzilay, Laura Salama, Molly Griffin, Grace Sollender, Aditya Bardia, Constance Lehman, Julliette M. Buckley, Suzanne B. Coopey, Fernanda Polubriaginof, et al.

    Extracting information from electronic medical record is a time-consuming and expensive process when done manually. Rule-based and machine learning techniques are two approaches to solving this problem. In this study, we trained a machine learning model on pathology reports to extract pertinent tumor characteristics, which enabled us to create a large database of attribute searchable pathology reports. This database can be used to identify cohorts of patients with characteristics of interest.


    • 15 September 2016
      • Vol. 30  (9) , 787-99

    What's New in Genetic Testing for Cancer Susceptibility?

    by Jennifer K Plichta, Molly Griffin, Joseph Thakuria, Kevin S Hughes

    The advent of next-generation sequencing, and its transition further into the clinic with the US Food and Drug Administration approval of a cystic fibrosis assay in 2013, have increased the speed and reduced the cost of DNA sequencing. Coupled with a historic ruling by the Supreme Court of the United States that human genes are not patentable, these events have caused a seismic shift in genetic testing in clinical medicine. More labs are offering genetic testing services; more multigene panels are available for gene testing; more genes and gene mutations are being identified; and more variants of uncertain significance, which may or may not be clinically actionable, have been found. All these factors, taken together, are increasing the complexity of clinical management. While these developments have led to a greater interest in genetic testing, risk assessment, and large-scale population screening, they also present unique challenges. The dilemma for clinicians is how best to understand and manage this rapidly growing body of information to improve patient care. With millions of genetic variants of potential clinical significance and thousands of genes associated with rare but well-established genetic conditions, the complexities of genetic data management clearly will require improved computerized clinical decision support tools, as opposed to continued reliance on traditional rote, memory-based medicine.


  • The Role of Micro-CT in 3D Histology Imaging

    by Michael Senter-Zapata, Kunal Patel, Pinky A. Bautista, Molly Griffin, James Michaelson, Yukako Yagi

    Objectives: 3D histology tissue modeling is a useful analytical technique for understanding anatomy and disease at the cellular level. However, the current accuracy of 3D histology technology is largely unknown, and errors, misalignment and missing information are common in 3D tissue reconstruction. We used micro-CT imaging technology to better understand these issues and the relationship between fresh tissue and its 3D histology counterpart. Methods: We imaged formalin-fixed and 2% Lugol-stained mouse brain, human uterus and human lung tissue with micro-CT. We then conducted image analyses on the tissues before and after paraffin embedding using 3D Slicer and ImageJ software to understand how tissue changes between the fixation and embedding steps. Results: We found that all tissue samples decreased in volume by 19.2-61.5% after embedding, that micro-CT imaging can be used to assess the integrity of tissue blocks, and that micro-CT analysis can help to design an optimized tissue-sectioning protocol. Conclusions: Micro-CT reference data help to identify where and to what extent tissue was lost or damaged during slide production, provides valuable anatomical information for reconstructing missing parts of a 3D tissue model, and aids in correcting reconstruction errors when fitting the image information in vivo and ex vivo.


  • Open Access

    Prediction of primary breast cancer size and T-stage using micro-computed tomography in lumpectomy specimens

    by Wafa M. Sarraj, Rong Tang, Anas L. Najjar, Molly Griffin, Anthony H. Bui, Alan Zambeli-Ljepovic, Mike Senter-Zapata, Maya Lewin-Berlin, Leopoldo Fernandez, Juliette Buckley, et al.


  • Open Access

    The Role of Micro CT in the Imaging of Cancer

    by M. Griffin, P. Anand, R. Tang, A. Zambeli-Ljepovic, M. Senter-Zapata, M. Lewin-Berlin, A. Bui, J. Singh, K. Patel, W. Sarraj, et al.